Abstract
Primary drug resistance (PDR) of Mycobacterium tuberculosis is detected in more than 34,5% new cases in Belarus and the portion increases annually. Gomel region has the highest level of HIV associated tuberculosis (TB) in Belarus (about 5,4% of new cases).
The aim of study was to investigate PDR incidence and spectrum in HIV-positive patients in comparison with HIV-negative ones.
We investigated 100 HIV-positive and 133 HIV-negative new TB cases. The groups were statistically equal by gender and age.
PDR was detected by MBT cultivation on Loewenstein-Jensen medium.
The results of study are represented in the table:
DR spectrum | HIV-positive | HIV-negative | Reliable difference |
PDR | 70,0% | 54,1% | No (p>0,05) |
Mono PDR | 13,3% | 10,5% | No (p>0,05) |
Multiple PDR (isoniazid+ rifampicin) | 56,5% | 43,6% | No (p>0,05) |
Summary PDR for isoniazid+ rifampicin+streptomycin | 57,4% | 51,4% | No (p>0,05) |
Extensive PDR (isoniazid+ rifampicin+fluoroquinolones+at least one of three injectable second-line drugs (amikacin, capreomycin or kanamycin) | 1,6% | 2,0% | No (p>0,05) |
Neither PDR proportion no PDR spectrum reliable difference was found in groups of HIV-positive and HIV-negative patients.
HIV-positivity was not concluded to be a reliable risk factor of PDR occurrence and didn't influence PDR spectrum.
- Copyright ©the authors 2016